Biotechnology

Abbvie

UCB's Bimzelx Beats AbbVie's Skyrizi in Head-to-Head Psoriatic Arthritis Study with Superior Joint Outcomes

Multiple Brokerages Adjust AbbVie Ratings as Q1 Earnings Beat Expectations

Mubadala Increases Stakes in AbbVie and Match Group, Reduces CVS and Gilead Holdings in Q1

AbbVie's Ekali approved by NMPA for combination therapy in R/R follicular lymphoma

AbbVie Reports Record Sales in 2025, Achieves 8.6% Sales Growth

Wesbanco Bank Inc. Reduces AbbVie Holdings

AbbVie Emphasizes New Long-term Data on IBD Treatment Standards at Digestive Disease Week

Guggenheim Reiterates Buy Rating on AbbVie

Bank of America Upgrades AbbVie’s Stock Rating to Buy

NY State Teachers Retirement System Reduces Holdings in AbbVie

Abbvie released FY2026 Q1 earnings on April 29 Pre-Market (EST), actual revenue USD 15 B (forecast USD 14.72 B), actual EPS USD 0.39 (forecast USD 1.254)

AbbVie Submits Application to FDA for RINVOQ® for Alopecia Areata

AbbVie's RINVOQ Outperformed HUMIRA in Clinical Study

AbbVie Submits Regulatory Application for SKYRIZI® to Treat Crohn's Disease to FDA

Richard C. Young & CO. Increased Holdings in AbbVie

AbbVie Receives FDA Complete Response Letter for BotulinumtoxinE Application

AbbVie's Wrinkle Treatment Rejected by FDA Due to Manufacturing Issues

Technical Tip: Unable to Load Part of the Website

AbbVie Announces $1.4 Billion Investment for Manufacturing Park

Abbvie to Release FY2026 Q1 Earnings on April 29 Pre-Market EST, Forecast Revenue USD 14.72 B, EPS USD 1.3632

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

UCBJY

LABU

SBIO

ARKG

UCB announced positive results from the phase 3 BE BOLD trial, showing bimekizumab outperformed risankizumab in treating active psoriatic arthritis. At week 16, 49.1% of bimekizumab patients achieved ACR50 compared to 38.4% for risankizumab. Early improvements were noted as early as week 4. No new safety concerns were reported, although mild to moderate candida infections were more common with bimekizumab.

PharmaTimes

UCB S.A.

United Community Banks

Direxion S&P Biotech Bull 3X

VanEck Biotech ETF

Invesco Nasdaq Biotechnology ETF

ALPS Medical Breakthrough

SPDR S&P Biotech

iShares Biotechnology ETF

Ark Genomic Revolution ETF

iShares US Pharma

VG Health

Health Care Select Sector SPDR

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

iShares Global Healthcare

Proshares Ultra Nasdaq Biotech

UCB reports positive outcomes for bimekizumab in psoriatic arthritis

ABBV

In today's trading, U.S. semiconductor stocks like Nvidia and AMD saw significant declines, while the healthcare sector, led by Eli Lilly and AbbVie, showed gains. The market sentiment is cautious due to concerns over the global chip shortage, but optimism in healthcare suggests a shift in investor interest. Recommendations include increasing healthcare allocations and considering semiconductor stocks for risk-tolerant investors, emphasizing the importance of diversification.

- The U.S. stock market showed mixed results, with technology stocks, notably semiconductors like Nvidia and AMD, experiencing declines amid pressures in the industry.  
- In contrast, the healthcare sector thrived with gains from Eli Lilly and AbbVie due to strong earnings and positive clinical news, attracting investor interest.  
- Strategic recommendations suggest investors increase healthcare sector allocations while considering the semiconductor weaknesses as potential buying opportunities for those willing to endure short-term fluctuations.

Investinglive

Eli Lilly

T-Rex 2X Inverse NVIDIA Daily Target ETF

Direxion Daily NVDA Bear 1X ETF

Direxion Daily NVDA Bull 2X Shares

GraniteShares 2x Long NVDA Daily ETF

Direxion Semicon Bear 3X

Direxion Daily AMD Bear 1X Shares

Direxion Daily AMD Bull 2X Shares

Direxion Daily LLY Bull 2X Shares

AXS 1.5X NVDA Bear Daily ETF

GraniteShares 2x Long AMD Daily ETF

GraniteShares 2x Short NVDA Daily ETF

NVIDIA

Intel

NVIDIA Corporation

Tech turmoil: Semiconductor stocks slide, healthcare finds footing

AbbVie and CVS Health appear expensive with trailing P/E multiples over 40, but non-recurring expenses inflate these figures. AbbVie’s forward P/E is 15, while CVS Health’s is 13, indicating they may be undervalued. AbbVie faced a significant drop in net income due to a $2.7 billion charge, while CVS reported a $4 billion loss from goodwill impairment. Both companies show potential for better performance, making them attractive investment options despite their current valuations.

nasdaq

CVS Health

S&P 500

2 Stocks That Are Much Cheaper Than They Look

PILL

In turbulent markets, investors favor high-dividend stocks. Benzinga highlights three healthcare stocks: AbbVie (3.30% yield), GSK (3.58% yield), and Bristol-Myers Squibb (4.40% yield). Analysts provide ratings and price targets, with AbbVie receiving an Overweight rating and a price target increase. GSK's stock was downgraded by Barclays but upgraded by Jefferies. Bristol-Myers Squibb announced a partnership for early-stage programs. Real-time updates are available on Benzinga's platform.

benzinga_article

Bristol Myers Squibb

Direxion Pharma & Medical Bull 3X

Piper Sandler Cos

Barclays

Jefferies Financial

Bank of America

Hengrui Pharma

HENGRUI PHARMA

GlaxoSmithKline plc

GSK plc Sponsored ADR

Bristol-Myers Squibb Company

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

Mission Wealth Management LP reduced its holdings in AbbVie Inc. (NYSE:ABBV) by 20.5% in Q4, now owning 37,264 shares valued at $8.5 million. Other investors like Wellington Management and Vanguard increased their stakes significantly. AbbVie reported Q1 earnings of $2.65 EPS, exceeding estimates, with revenue of $15 billion. The company also announced a quarterly dividend of $1.73 per share, yielding 3.3%. Analysts maintain a consensus rating of 'Moderate Buy' with a price target of $253.43.

Market Beat

Raymond James Financial

AllianceBernstein

Goldman Sachs

Bank of Montreal

RAYMOND JAMES FINANCIAL INC 6.375%DEP SHS REP 1/40TH FXD FLTG SER B

GS Hldg R

Mission Wealth Management LP Lowers Holdings in AbbVie Inc. $ABBV

RiverFront Investment Group LLC increased its holdings in AbbVie Inc. (NYSE:ABBV) by 41.7% in Q4, owning 30,577 shares valued at $6.99 million. Other institutional investors, including Vanguard and Wellington Management, also raised their stakes. Insider selling occurred, with EVP Perry C. Siatis selling 22,381 shares. Analysts have mixed ratings on AbbVie, with a consensus rating of 'Moderate Buy' and an average target price of $253.43.

Legal & General Group Plc

Ameriprise Financial

Citigroup

Evercore

CITIGROUP INC 6.250 NON CUM SER II PFD WI

AbbVie Inc. $ABBV Shares Purchased by RiverFront Investment Group LLC

Wall Street Zen downgraded AbbVie (NYSE:ABBV) from a 'strong-buy' to a 'buy' rating. Other brokerages have varied opinions, with DZ Bank upgrading to 'strong-buy' and Bank of America setting a $234 price target. AbbVie reported Q1 earnings of $2.65 EPS, exceeding estimates, with revenue up 12.4% year-over-year. The stock has a consensus rating of 'Moderate Buy' and a price target of $253.43.

Texas Capital

AbbVie (NYSE:ABBV) Rating Lowered to Buy at Wall Street Zen

Abbvie(ABBV.US)